Anaphylaxis
For patient information, click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Dushka Riaz, MD
Synonyms and keywords: Anaphylactic reaction
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Anaphylaxis is an acute systemic Type I Hypersensitivity allergic reaction. Anaphylaxis occurs when a person is exposed to a trigger allergen that they have been previously sensitized to. Anaphylaxis can occur through ingestion, skin contact or injection. [1] The allergen causes a release of mast cells into the circulation. [2] It is marked by life threatening compromise of airway, breathing and circulation. [3] Common causes in children are usually food whereas in adults it is usually linked to medications and insect stings. [4] The mainstay of prevention is to avoid the allergen. [1] The mainstay of treatment is epinephrine. [5]
References
- ↑ 1.0 1.1 LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Yu JE, Lin RY (2018). “The Epidemiology of Anaphylaxis”. Clin Rev Allergy Immunol. 54 (3): 366–374. doi:10.1007/s12016-015-8503-x. PMID 26357949.
- ↑ Reber LL, Hernandez JD, Galli SJ (2017). “The pathophysiology of anaphylaxis”. J Allergy Clin Immunol. 140 (2): 335–348. doi:10.1016/j.jaci.2017.06.003. PMC 5657389. PMID 28780941.
- ↑ Commins SP (2017). “Outpatient Emergencies: Anaphylaxis”. Med Clin North Am. 101 (3): 521–536. doi:10.1016/j.mcna.2016.12.003. PMC 5381731. PMID 28372711.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID 10.1542/peds.2016-4006 DOI: 10.1542/peds.2016-4006 Check
|pmid=value (help).
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
The term comes from the Greek words ana (against) and phylaxis (protection).
Discovery
Anaphylaxis was first discovered by Charles Richet and Paul Portier, who were French physiologists in 1913. [1] During their study of Physalia, Portugese man- o -war toxin, they began a series of experiments on a dog. They injected the toxin in the dog and repeated this days later. [2] They found an exaggerated immune response resulting in the dog experiencing collapse of the airway, breathing, and circulatory systems. [1] They named it anaphylaxis as they felt the phenomenon was the opposite of protection, or prophylaxis. [3] Richet was awarded a Noble Prize for his work in 1913. [4]
Landmark Events in the Development of Treatment Strategies
In the year 1937, Daniel Bovet discovered antihistamines, and cortisone was introduced in the year 1949. [5]
References
- ↑ 1.0 1.1 Ring J, Behrendt H, de Weck A (2010). “History and classification of anaphylaxis”. Chem Immunol Allergy. 95: 1–11. doi:10.1159/000315934. PMID 20519878.
- ↑ Tan SY, Yamanuha J (2010). “Charles Robert Richet (1850-1935): discoverer of anaphylaxis”. Singapore Med J. 51 (3): 184–5. PMID 20428737.
- ↑ Richet G (2003). “[The discovery of anaphylaxis, a brief but triumphant encounter of two physiologists (1902)]”. Hist Sci Med. 37 (4): 463–9. PMID 14989211.
- ↑ Mazana J, Ariño MR (1991). “Charles Robert Richet and some milestones in the history of allergies”. J Investig Allergol Clin Immunol. 1 (2): 93–100. PMID 1669573.
- ↑ LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Anaphylaxis may be classified into 2 subtypes/groups: Immunologic-IgE mediated and Immunologic-non-IgE mediated. [1]
The diagnostic criteria must have one of the three of the following: [2]
- 1. Acute onset of disruption of the skin or mucosal tissue with either reduced blood pressure or decreased perfusion and/or respiratory compromise.
- 2. Exposure to a likely allergen followed with two of the following: involvement of mucosal tissue, respiratory compromise, gastrointestinal disturbances, or reduced blood pressure
- 3. Reduced blood pressure after exposure to a known allergen
Classification
Anaphylaxis may be classified into two groups: [1]
- Immunologic-IgE: whose causes include food allergens, medications, latex, airborne allergens
- Immunologic-non-IgE: whose causes include IVIG, NSAIDS and aspirin
There are also three pattern classifications:
- Uniphasic which resolves in an hour
- Biphasic which includes recurrence even without repeated exposure [3]
- Protracted which can lasts for days [4]
Anaphylaxis can also be categorized according to the cause: [5]
- Anaphylaxis caused by food allergens
- Anaphylaxis caused by drug allergens
- Anaphylaxis caused by insect venom
- Anaphylaxis caused by physical factors
- Anaphylaxis caused by inhaled allergens
- Anaphylaxis caused by allergen contact
- Anaphylaxis caused by mast cell disorders
References
- ↑ 1.0 1.1 LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A; et al. (2006). “Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium”. J Allergy Clin Immunol. 117 (2): 391–7. doi:10.1016/j.jaci.2005.12.1303. PMID 16461139.
- ↑ Lee S, Sadosty AT, Campbell RL (2016). “Update on biphasic anaphylaxis”. Curr Opin Allergy Clin Immunol. 16 (4): 346–51. doi:10.1097/ACI.0000000000000279. PMID 27253484.
- ↑ Zisa G, Riccobono F, Calamari AM, D’Antonio CD, Galimberti M (2009). “A case of protracted hypotension as unique symptom of a biphasic anaphylaxis to amoxicillin”. Eur Ann Allergy Clin Immunol. 41 (2): 60–1. PMID 19585862.
- ↑ Tanno LK, Chalmers RJ, Calderon MA, Aymé S, Demoly P, on behalf the Joint Allergy Academies (2017). “Reaching multidisciplinary consensus on classification of anaphylaxis for the eleventh revision of the World Health Organization’s (WHO) International Classification of Diseases (ICD-11)”. Orphanet J Rare Dis. 12 (1): 53. doi:10.1186/s13023-017-0607-3. PMC 5356259. PMID 28302183.
References
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
The progression to anaphylaxis usually involves an IgE-mediated or non IgE-mediated response. It is a medical emergency that involves multiple systems. [1] The condition involves pulmonary, gastrointestinal, cardiovascular and integumentary systems and can lead to cardiorespiratory arrest. [2]
Pathophysiology
Anaphylaxis is usually caused by food, particularly peanuts, drugs, and insect venoms. [3] [4] There have also been cases of idiopathic anaphylaxis. [5] [6] Anaphylaxis arises from mast cell and basophil degranulation after repeated exposure to an antigen. This results in a type 1 hypersensitivity reaction. The IgE then crosslinks and aggregates with receptors resulting in the release of histamine, proteoglycans, and tryptase. This results in arachidonic acid metabolites being released with further consequences. The reaction as a whole leads to vasodilation, increase heart rate, bronchoconstriction, and hypoperfusion of vital organs. [1]
Specifically, histamine causes vasodilation and increased heart rate and permeability which ultimately leads to the hypoperfusion of various tissues. Prostaglandin D2 causes bronchoconstriction of both cardiac and pulmonary systems culminating in peripheral vasodilation and further hypoperfusion of tissues. Leukotrienes and platelet activation factor also contribute to vascular permeability, along with bronchoconstriction and airway remodeling. Finally, TNF-alpha activate neutrophils which increases the synthesis of chemokines. [7] [1]
Anaphylaxis can be divided into IgE-dependent and IgE-independent mechanisms. IgE levels are higher in those patients that have allergies. Once IgE binds to FcεRI on mast cells and basophils this releases histamine and other inflammatory mediators. On repeat exposure to the antigen, these IgE aggregates lead to anaphylaxis. [8] IgE levels are even used during the diagnosis of allergies to determine what allergens a patient is susceptible to. [9] Meanwhile, in IgE-independent reactions, IgG mechanisms were also found to lead to anaphylaxis, which has largely been studied in mice. A single episode of anaphylaxis may also be caused by simultaneous IgG and IgE-mediated pathways. [10]
Genetics
Genes involved in the pathogenesis of anaphylaxis include:[11] [12] [13] [14] [15] [16] [17] [18] [19]
- Polymorphisms in IL-10, IL-13, IL-4Rα are linked to anaphylaxis to drugs and latex.
- PAF-AH activity levels are correlated inversely with the severity of anaphylaxis.
- Variations in angiotensinogen MM genotype with low levels of angiotensin are linked with high rates of hymenoptera venom allergy.
- Patients with peanut allergies and low serum ACE levels are linked with high rates of pharyngeal edema.
- Activating mutation in c-KIT and D816V are associated with mastocytosis and hyperresponsivity of their mast cells with resulting increasing severity of anaphylaxis rates.
- Anaphylaxis occurs more commonly in women, though the mechanism is not clear.
Associated Conditions
Conditions associated with anaphylaxis include the following and are associated with poor prognosis: [20] [21]
- Asthma
- Cardiovascular disease
- Antihypertensive medication use
Gross Pathology
On gross pathology, basophil and mast cell degranulation are characteristic findings of anaphylaxis. [1]
Microscopic Pathology
On microscopic histopathological analysis, upper airways showing eosinophils due to edema are characteristic findings of anaphylaxis. Tissue sections can also show tryptase, which is an enzyme specific to mast cells. [22]
References
- ↑ 1.0 1.1 1.2 1.3 “StatPearls”. 2021. PMID 29489197.
- ↑ LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Sampson HA, Muñoz-Furlong A, Bock SA, Schmitt C, Bass R, Chowdhury BA; et al. (2005). “Symposium on the definition and management of anaphylaxis: summary report”. J Allergy Clin Immunol. 115 (3): 584–91. doi:10.1016/j.jaci.2005.01.009. PMID 15753908.
- ↑ Kemp SF, Lockey RF (2002). “Anaphylaxis: a review of causes and mechanisms”. J Allergy Clin Immunol. 110 (3): 341–8. doi:10.1067/mai.2002.126811. PMID 12209078.
- ↑ Lenchner K, Grammer LC (2003). “A current review of idiopathic anaphylaxis”. Curr Opin Allergy Clin Immunol. 3 (4): 305–11. doi:10.1097/00130832-200308000-00012. PMID 12865776.
- ↑ Ring J, Darsow U (2002). “Idiopathic anaphylaxis”. Curr Allergy Asthma Rep. 2 (1): 40–5. doi:10.1007/s11882-002-0036-8. PMID 11895624.
- ↑ Peavy RD, Metcalfe DD (2008). “Understanding the mechanisms of anaphylaxis”. Curr Opin Allergy Clin Immunol. 8 (4): 310–5. doi:10.1097/ACI.0b013e3283036a90. PMC 2683407. PMID 18596587.
- ↑ Kraft S, Kinet JP (2007). “New developments in FcepsilonRI regulation, function and inhibition”. Nat Rev Immunol. 7 (5): 365–78. doi:10.1038/nri2072. PMID 17438574.
- ↑ Hamilton RG, MacGlashan DW, Saini SS (2010). “IgE antibody-specific activity in human allergic disease”. Immunol Res. 47 (1–3): 273–84. doi:10.1007/s12026-009-8160-3. PMID 20066506.
- ↑ Finkelman FD, Khodoun MV, Strait R (2016). “Human IgE-independent systemic anaphylaxis”. J Allergy Clin Immunol. 137 (6): 1674–1680. doi:10.1016/j.jaci.2016.02.015. PMC 7607869 Check
|pmc=value (help). PMID 27130857. - ↑ Reber LL, Hernandez JD, Galli SJ (2017). “The pathophysiology of anaphylaxis”. J Allergy Clin Immunol. 140 (2): 335–348. doi:10.1016/j.jaci.2017.06.003. PMC 5657389. PMID 28780941.
- ↑ Apter AJ, Schelleman H, Walker A, Addya K, Rebbeck T (2008). “Clinical and genetic risk factors of self-reported penicillin allergy”. J Allergy Clin Immunol. 122 (1): 152–8. doi:10.1016/j.jaci.2008.03.037. PMID 18538381.
- ↑ Brown RH, Hamilton RG, Mintz M, Jedlicka AE, Scott AL, Kleeberger SR (2005). “Genetic predisposition to latex allergy: role of interleukin 13 and interleukin 18”. Anesthesiology. 102 (3): 496–502. doi:10.1097/00000542-200503000-00004. PMID 15731584.
- ↑ Niedoszytko M, Ratajska M, Chełmińska M, Makowiecki M, Malek E, Siemińska A; et al. (2010). “The angiotensinogen AGT p.M235T gene polymorphism may be responsible for the development of severe anaphylactic reactions to insect venom allergens”. Int Arch Allergy Immunol. 153 (2): 166–72. doi:10.1159/000312634. PMID 20413984.
- ↑ Summers CW, Pumphrey RS, Woods CN, McDowell G, Pemberton PW, Arkwright PD (2008). “Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center”. J Allergy Clin Immunol. 121 (3): 632–638.e2. doi:10.1016/j.jaci.2007.12.003. PMID 18207562.
- ↑ Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y; et al. (1995). “Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder”. Proc Natl Acad Sci U S A. 92 (23): 10560–4. doi:10.1073/pnas.92.23.10560. PMC 40651. PMID 7479840.
- ↑ Gülen T, Ljung C, Nilsson G, Akin C (2017). “Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis”. J Allergy Clin Immunol Pract. 5 (5): 1248–1255. doi:10.1016/j.jaip.2017.02.008. PMID 28351784.
- ↑ Webb LM, Lieberman P (2006). “Anaphylaxis: a review of 601 cases”. Ann Allergy Asthma Immunol. 97 (1): 39–43. doi:10.1016/S1081-1206(10)61367-1. PMID 16892779.
- ↑ Worm M, Edenharter G, Ruëff F, Scherer K, Pföhler C, Mahler V; et al. (2012). “Symptom profile and risk factors of anaphylaxis in Central Europe”. Allergy. 67 (5): 691–8. doi:10.1111/j.1398-9995.2012.02795.x. PMID 22335765.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1186/s13223-018-0283-4 Check
|pmid=value (help). - ↑ Lee S, Hess EP, Nestler DM, Bellamkonda Athmaram VR, Bellolio MF, Decker WW; et al. (2013). “Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis”. J Allergy Clin Immunol. 131 (4): 1103–8. doi:10.1016/j.jaci.2013.01.011. PMID 23453138.
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1007/s12024-016-9799-4 Check
|pmid=value (help).
References
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Vidit Bhargava, M.B.B.S [2]Soumya Sachdeva, , Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Anaphylaxis can have IgE-mediated, non IgE-mediated and nonimmunologic triggers. IgE mediated allergens include reactions to food, medications and animal dander. Non-IgE mediated reactions can be caused by IVIG, biologic agents and NSAIDs. Nonimmunologic triggers to anaphylaxis include radiocontrast media, opiates, and changes in temperature. [1] Adult cases are more commonly caused by medications and insect stings while children are more triggered by food. [2]
Life Threatening Causes
Anaphylaxis is itself a life-threatening condition caused by various allergens. [1]
Causes
Common Causes
Anaphylaxis can occur in response to any allergen. Common causes include: [3] [4] [5] [6] [7] [8] [9] [10] [11]
- Drug allergies (acetaminophen, penicillins, Prednisolone, cephalosporins, amphotericin B, nitrofurantoin, quinolones)
- Food allergies (peanuts, milk, eggs, seafood, nuts, grains, beans, gelatin in capsules)
- Insect bites/stings (yellow jacket, yellow and baldfaced hornets, paper wasp, honey bee, imported fire ants)
- Nonpollen allergen extracts (dust mites, dander of cats, dogs, horses and laboratory animals)
Causes by Organ System
Causes in Alphabetical Order
References
- ↑ 1.0 1.1 LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Commins SP (2017). “Outpatient Emergencies: Anaphylaxis”. Med Clin North Am. 101 (3): 521–536. doi:10.1016/j.mcna.2016.12.003. PMC 5381731. PMID 28372711.
- ↑ Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J; et al. (2011). “World Allergy Organization anaphylaxis guidelines: summary”. J Allergy Clin Immunol. 127 (3): 587-93.e1-22. doi:10.1016/j.jaci.2011.01.038. PMID 21377030.
- ↑ Boyce JA, Assa’ad A, Burks AW, Jones SM, Sampson HA, Wood RA; et al. (2010). “Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report”. J Allergy Clin Immunol. 126 (6): 1105–18. doi:10.1016/j.jaci.2010.10.008. PMC 4241958. PMID 21134568.
- ↑ Sicherer SH, Sampson HA (2014). “Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment”. J Allergy Clin Immunol. 133 (2): 291–307, quiz 308. doi:10.1016/j.jaci.2013.11.020. PMID 24388012.
- ↑ Fischer D, Vander Leek TK, Ellis AK, Kim H (2018). “Anaphylaxis”. Allergy Asthma Clin Immunol. 14 (Suppl 2): 54. doi:10.1186/s13223-018-0283-4. PMC 6156836. PMID 30263034.
- ↑ “StatPearls”. 2021. PMID 29489197.
- ↑ Tupper J, Visser S (2010). “Anaphylaxis: A review and update”. Can Fam Physician. 56 (10): 1009–11. PMC 2954079. PMID 20944042.
- ↑ Worm M, Babina M, Hompes S (2013). “Causes and risk factors for anaphylaxis”. J Dtsch Dermatol Ges. 11 (1): 44–50. doi:10.1111/j.1610-0387.2012.08045.x. PMID 23181736.
- ↑ Poziomkowska-Gęsicka I, Kurek M (2020). “Clinical Manifestations and Causes of Anaphylaxis. Analysis of 382 Cases from the Anaphylaxis Registry in West Pomerania Province in Poland”. Int J Environ Res Public Health. 17 (8). doi:10.3390/ijerph17082787. PMC 7215547 Check
|pmc=value (help). PMID 32316622 Check|pmid=value (help). - ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1067/mai.2002.126811 Check
|pmid=value (help).
Differentiating Anaphylaxis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Anaphylaxis must be differentiated from carcinoid syndrome, globus hystericus, hereditary angioedema, pheochromocytoma, pulmonary embolism, scombroid intoxication, systemic mastocytosis, vagal reactions, irritable bowel syndrome, Crohn’s disease, malignant neoplasm of the small intestine, benign cutaneous flushing, asthma exacerbation, and medullary thyroid carcinoma. [1]
Differentiating Anaphylaxis from other Diseases
Pseudoanaphylactic Reactions (Conditions that Mimic Anaphylaxis)
First administration of the following drugs or agents:
- Aspirin
- Contrast media (first contact)
- Pentamidine (first contact)
- Polymyxin (first contact)
Conditions that may mimic anaphylaxis include the following:
- Carcinoid Syndrome
- Globus hystericus
- Hereditary angioedema
- Pheochromocytoma
- Pulmonary Embolism
- Scombroid intoxication
- Systemic Mastocytosis
- Vagal reactions
| Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symptoms | Physical examination | ||||||||||||||||||||||||
| Lab Findings | Imaging | Histopathology | |||||||||||||||||||||||
| Abdominal pain | Diarrhea | Flushing | Dyspnea | Palpitations | Other symptoms | Wheezing | Telangiectasia | Hypotension | Tachycardia | Systolic murmur of tricuspid regurgitation | Other physical findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | Serum Chromogranin A (CgA) | Other markers | Abdominal computed tomography (CT) | Abdominal MRI | Somatostatin receptor scintigraphy [SRS], or Octreoscan | Metaiodobenzylguanidine (MIBG) scintigraphy | Other diagnostic studies | Transthoracic echocardiography | |||||
| Carcinoid Syndrome[2][3][4][5][6][7][8][9][10] | Neuroendocrine tumor of midgut [11][12][13][14] | +
Mild |
+
|
+ | + | + |
Metastatic tumors in the liver: Right upper quadrant pain, hepatomegaly, and early satiety |
+ | +/- | +/- | + | + | – | + | + |
|
|
|
+
|
+ |
|
|
|
|
|
| Neuroendocrine tumor of lung[15][16][17][18] | + | + | + | + | + |
|
+ | +/- | +/- | + | + | – | + | + |
|
Sensitive for detection of liver metastases if present | + | + |
|
– | Typical low-grade:bland cells containing regular round nuclei with finely dispersed chromatin and inconspicuous small nucleoli.Mitotic figures are scarce and necrosis is absent.
Intermediate-grade atypical: presence of Neuroendocrine morphology and either necrosis or 2 to 10 mitoses per 10 HPF |
| |||
| Irritable Bowel Syndrome[19][20][21][22] | +
Perioidic |
|
– | – | – | – | – | – | – | – | – | – | – | – | – | – |
|
– | – | Rome IV criteria
•Related to defecation •Associated with a change in stool frequency •Associated with a change in stool form (appearance) |
|||||
| Malignant neoplasms of small intestine[23][24][25] | +/- | +/- | – | – | +/- |
|
– | – | +/- | – | * Abdominal mass | – | + | Abdominal CT scan may be diagnostic of small intestine cancer. Findings on CT scan suggestive of small intestine cancer include intrinsic mass with a short segment of bowel wall thickening | MRI and MRI enteroscopy are other advance modalities to diagnose and stage small intestinal cancers | – | – | Enteroscopy, capsule endoscopy and double balloon enteroscopy |
|
Biopsy and histopathology | |||||
| Crohn disease[26][27][28][29] | +/- | – | – | – |
|
– | – | – | – | – |
|
– | – |
|
– | – |
|
– |
|
|
|||||
| Benign cutaneous flushing[30] | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |||
| Systemic mastocytosis[31][32][33][34][35] | + | + | + | + | – | +/- | +/- | + | – | – | – | – | – | – | |||||||||||
| Asthma exacerbation[36] | –[37][38] | – | – | + | + | + | – | – | + | – | – | – | Chest X ray | ||||||||||||
| Anaphylaxis[39][40][41][42][43] | + | -/+ | + | + | + | +/- | – | + | + | – | – | – | – | – | – |
|
– | – | History of exposure to insect stings,food alllergy,rubber latex,food additives,,allergy to medications,physical factors such s excercise and cold | ||||||
| Histaminergic Angioedema[44][45][46][47][48] | +/- | +/- | + | + | + |
|
+ | – | + | + | – | – | – | – |
|
– | – | – |
|
– | – | – |
| ||
| Medullary Thyroid Carcinoma[49][50][51][52] | – | +/- | +/- | +/- | – | – | – | – | – | – | – | – |
|
– | – | – |
|
– |
|
|
|||||
References
- ↑ LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP (August 2018). “Carcinoid syndrome: update on the pathophysiology and treatment”. Clinics (Sao Paulo). 73 (suppl 1): e490s. doi:10.6061/clinics/2018/e490s. PMC 6096975. PMID 30133565.
- ↑ Hegyi J, Schwartz RA, Hegyi V (January 2004). “Pellagra: dermatitis, dementia, and diarrhea”. Int. J. Dermatol. 43 (1): 1–5. PMID 14693013.
- ↑ Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E (May 2004). “Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours”. Nucl Med Commun. 25 (5): 445–9. PMID 15100502.
- ↑ Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, Villano C, Maccauro M, Bombardieri E (May 2004). “Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours”. Nucl Med Commun. 25 (5): 445–9. PMID 15100502.
- ↑ Bora, ManashKumar; Vithiavathi, S (2012). “Primary bronchial carcinoid: A rare differential diagnosis of pulmonary koch in young adult patient”. Lung India. 29 (1): 59. doi:10.4103/0970-2113.92366. ISSN 0970-2113.
- ↑ Yazıcıoğlu A, Yekeler E, Bıcakcıoğlu P, Ozaydın E, Karaoğlanoğlu N (December 2012). “Synchronous bilateral multiple typical pulmonary carcinoid tumors: a unique case with 10 typical carcinoids”. Balkan Med J. 29 (4): 450–2. doi:10.5152/balkanmedj.2012.081. PMC 4115868. PMID 25207053.
- ↑ Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, Rubinstein R, Sachs J, Bocher M, Agranovicz S, Chisin R, Israel O (November 2003). “SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours”. Clin. Endocrinol. (Oxf). 59 (5): 565–73. PMID 14616879.
- ↑ van der Lely, Aart J.; Herder, Wouter W. de (2005). “Carcinoid syndrome: diagnosis and medical management”. Arquivos Brasileiros de Endocrinologia & Metabologia. 49 (5): 850–860. doi:10.1590/S0004-27302005000500028. ISSN 0004-2730.
- ↑ Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC (April 2017). “Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study”. Lancet Oncol. 18 (4): 525–534. doi:10.1016/S1470-2045(17)30110-9. PMC 6066284. PMID 28238592.
- ↑ Sjöblom SM (September 1988). “Clinical presentation and prognosis of gastrointestinal carcinoid tumours”. Scand. J. Gastroenterol. 23 (7): 779–87. PMID 3227292.
- ↑ Ganeshan D, Bhosale P, Yang T, Kundra V (October 2013). “Imaging features of carcinoid tumors of the gastrointestinal tract”. AJR Am J Roentgenol. 201 (4): 773–86. doi:10.2214/AJR.12.9758. PMID 24059366.
- ↑ Signs and symptoms of carcinoid syndrome. National Cancer Institute. http://www.cancer.gov/types/gi-carcinoid-tumors/patient/gi-carcinoid-treatment-pdq
- ↑ Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD (May 2005). “Current status of gastrointestinal carcinoids”. Gastroenterology. 128 (6): 1717–51. PMID 15887161.
- ↑ Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM (July 2008). “Bronchopulmonary neuroendocrine tumors”. Cancer. 113 (1): 5–21. doi:10.1002/cncr.23542. PMID 18473355.
- ↑ Jeung, Mi-Young; Gasser, Bernard; Gangi, Afshin; Charneau, Dominique; Ducroq, Xavier; Kessler, Romain; Quoix, Elisabeth; Roy, Catherine (2002). “Bronchial Carcinoid Tumors of the Thorax: Spectrum of Radiologic Findings”. RadioGraphics. 22 (2): 351–365. doi:10.1148/radiographics.22.2.g02mr01351. ISSN 0271-5333.
- ↑ Nessi R, Basso Ricci P, Basso Ricci S, Bosco M, Blanc M, Uslenghi C (April 1991). “Bronchial carcinoid tumors: radiologic observations in 49 cases”. J Thorac Imaging. 6 (2): 47–53. PMID 1649924.
- ↑ Melmon KL, Sjoerdsma A, Mason DT (October 1965). “Distinctive clinical and therapeutic aspects of the syndrome associated with bronchial carcinoid tumors”. Am. J. Med. 39 (4): 568–81. PMID 5831899.
- ↑ Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P (May 2008). “Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior”. Am. J. Gastroenterol. 103 (5): 1229–39, quiz 1240. doi:10.1111/j.1572-0241.2007.01740.x. PMID 18371141.
- ↑ Simren M, Palsson OS, Whitehead WE (April 2017). “Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice”. Curr Gastroenterol Rep. 19 (4): 15. doi:10.1007/s11894-017-0554-0. PMC 5378729. PMID 28374308.
- ↑ “American Gastroenterological Association medical position statement: irritable bowel syndrome”. Gastroenterology. 123 (6): 2105–7. December 2002. doi:10.1053/gast.2002.37095b. PMID 12454865.
- ↑ Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R (February 2016). “Bowel Disorders”. Gastroenterology. doi:10.1053/j.gastro.2016.02.031. PMID 27144627.
- ↑ McLaughlin PD, Maher MM (July 2013). “Primary malignant diseases of the small intestine”. AJR Am J Roentgenol. 201 (1): W9–14. doi:10.2214/AJR.12.8492. PMID 23789703.
- ↑ Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ, Longo WE (March 2007). “Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the connecticut tumor registry”. Arch Surg. 142 (3): 229–35. doi:10.1001/archsurg.142.3.229. PMID 17372046.
- ↑ Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J (December 2006). “Incidence and management of primary malignant small bowel cancers: a well-defined French population study”. Am. J. Gastroenterol. 101 (12): 2826–32. doi:10.1111/j.1572-0241.2006.00854.x. PMID 17026561.
- ↑ Hara AK, Swartz PG (2009). “CT enterography of Crohn’s disease”. Abdom Imaging. 34 (3): 289–95. doi:10.1007/s00261-008-9443-1. PMID 18649092.
- ↑ Baumgart, Daniel C; Sandborn, William J (2012). “Crohn’s disease”. The Lancet. 380 (9853): 1590–1605. doi:10.1016/S0140-6736(12)60026-9. ISSN 0140-6736.
- ↑ Feuerstein, Joseph D.; Cheifetz, Adam S. (2017). “Crohn Disease: Epidemiology, Diagnosis, and Management”. Mayo Clinic Proceedings. 92 (7): 1088–1103. doi:10.1016/j.mayocp.2017.04.010. ISSN 0025-6196.
- ↑ García-Bosch, O.; Ordás, I.; Aceituno, M.; Rodríguez, S.; Ramírez, A. M.; Gallego, M.; Ricart, E.; Rimola, J.; Panes, J. (2016). “Comparison of Diagnostic Accuracy and Impact of Magnetic Resonance Imaging and Colonoscopy for the Management of Crohn’s Disease”. Journal of Crohn’s and Colitis. 10 (6): 663–669. doi:10.1093/ecco-jcc/jjw015. ISSN 1873-9946.
- ↑ Izikson, Leonid; English, Joseph C.; Zirwas, Matthew J. (2006). “The flushing patient: Differential diagnosis, workup, and treatment”. Journal of the American Academy of Dermatology. 55 (2): 193–208. doi:10.1016/j.jaad.2005.07.057. ISSN 0190-9622.
- ↑ Hartmann, Karin; Escribano, Luis; Grattan, Clive; Brockow, Knut; Carter, Melody C.; Alvarez-Twose, Ivan; Matito, Almudena; Broesby-Olsen, Sigurd; Siebenhaar, Frank; Lange, Magdalena; Niedoszytko, Marek; Castells, Mariana; Oude Elberink, Joanna N.G.; Bonadonna, Patrizia; Zanotti, Roberta; Hornick, Jason L.; Torrelo, Antonio; Grabbe, Jürgen; Rabenhorst, Anja; Nedoszytko, Boguslaw; Butterfield, Joseph H.; Gotlib, Jason; Reiter, Andreas; Radia, Deepti; Hermine, Olivier; Sotlar, Karl; George, Tracy I.; Kristensen, Thomas K.; Kluin-Nelemans, Hanneke C.; Yavuz, Selim; Hägglund, Hans; Sperr, Wolfgang R.; Schwartz, Lawrence B.; Triggiani, Massimo; Maurer, Marcus; Nilsson, Gunnar; Horny, Hans-Peter; Arock, Michel; Orfao, Alberto; Metcalfe, Dean D.; Akin, Cem; Valent, Peter (2016). “Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology”. Journal of Allergy and Clinical Immunology. 137 (1): 35–45. doi:10.1016/j.jaci.2015.08.034. ISSN 0091-6749.
- ↑ Lee, Jason K; Whittaker, Scott J; Enns, Robert A; Zetler, Peter (2008). “Gastrointestinal manifestations of systemic mastocytosis”. World Journal of Gastroenterology. 14 (45): 7005. doi:10.3748/wjg.14.7005. ISSN 1007-9327.
- ↑ Horan RF, Austen KF (March 1991). “Systemic mastocytosis: retrospective review of a decade’s clinical experience at the Brigham and Women’s Hospital”. J. Invest. Dermatol. 96 (3): 5S–13S, discussion 13S–14S. PMID 2002264.
- ↑ Sokol, Harry; Georgin-Lavialle, Sophie; Grandpeix-Guyodo, Catherine; Canioni, Danielle; Barete, Stéphane; Dubreuil, Patrice; Lortholary, Olivier; Beaugerie, Laurent; Hermine, Olivier (2010). “Gastrointestinal involvement and manifestations in systemic mastocytosis”. Inflammatory Bowel Diseases. 16 (7): 1247–1253. doi:10.1002/ibd.21218. ISSN 1078-0998.
- ↑ Bedeir A, Jukic DM, Wang L, Mullady DK, Regueiro M, Krasinskas AM (November 2006). “Systemic mastocytosis mimicking inflammatory bowel disease: A case report and discussion of gastrointestinal pathology in systemic mastocytosis”. Am. J. Surg. Pathol. 30 (11): 1478–82. doi:10.1097/01.pas.0000213310.51553.d7. PMID 17063092.
- ↑ Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA, Gern J, Heymann PW, Martinez FD, Mauger D, Teague WG, Blaisdell C (March 2012). “Asthma outcomes: exacerbations”. J. Allergy Clin. Immunol. 129 (3 Suppl): S34–48. doi:10.1016/j.jaci.2011.12.983. PMC 3595577. PMID 22386508.
- ↑ Dougherty RH, Fahy JV (February 2009). “Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype”. Clin. Exp. Allergy. 39 (2): 193–202. doi:10.1111/j.1365-2222.2008.03157.x. PMC 2730743. PMID 19187331.
- ↑ Aldington S, Beasley R (May 2007). “Asthma exacerbations. 5: assessment and management of severe asthma in adults in hospital”. Thorax. 62 (5): 447–58. doi:10.1136/thx.2005.045203. PMC 2117186. PMID 17468458.
- ↑ Peavy RD, Metcalfe DD (August 2008). “Understanding the mechanisms of anaphylaxis”. Curr Opin Allergy Clin Immunol. 8 (4): 310–5. doi:10.1097/ACI.0b013e3283036a90. PMC 2683407. PMID 18596587.
- ↑ Tupper J, Visser S (October 2010). “Anaphylaxis: A review and update”. Can Fam Physician. 56 (10): 1009–11. PMC 2954079. PMID 20944042.
- ↑ Kemp SF, Lockey RF (September 2002). “Anaphylaxis: a review of causes and mechanisms”. J. Allergy Clin. Immunol. 110 (3): 341–8. PMID 12209078.
- ↑ Bjornsson HM, Graffeo CS (December 2010). “Improving diagnostic accuracy of anaphylaxis in the acute care setting”. West J Emerg Med. 11 (5): 456–61. PMC 3027438. PMID 21293765.
- ↑ “Usefulness and Limitations of Sequential Serum Tryptase for the Diagnosis of Anaphylaxis in 102 Patients – FullText – International Archives of Allergy and Immunology 2013, Vol. 160, No. 2 – Karger Publishers”.
- ↑ Busse PJ, Smith T (August 2017). “Histaminergic Angioedema”. Immunol Allergy Clin North Am. 37 (3): 467–481. doi:10.1016/j.iac.2017.03.001. PMID 28687103.
- ↑ Hahn J, Hoffmann TK, Bock B, Nordmann-Kleiner M, Trainotti S, Greve J (July 2017). “Angioedema”. Dtsch Arztebl Int. 114 (29–30): 489–496. doi:10.3238/arztebl.2017.0489. PMC 5569554. PMID 28818177.
- ↑ Bernstein JA, Cremonesi P, Hoffmann TK, Hollingsworth J (December 2017). “Angioedema in the emergency department: a practical guide to differential diagnosis and management”. Int J Emerg Med. 10 (1): 15. doi:10.1186/s12245-017-0141-z. PMC 5389952. PMID 28405953.
- ↑ Bernstein JA, Moellman J (November 2012). “Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema”. Int J Emerg Med. 5 (1): 39. doi:10.1186/1865-1380-5-39. PMC 3518251. PMID 23131076.
- ↑ Kaplan AP (June 2008). “Angioedema”. World Allergy Organ J. 1 (6): 103–13. doi:10.1097/WOX.0b013e31817aecbe. PMC 3651192. PMID 23282406.
- ↑ Pacini F, Castagna MG, Cipri C, Schlumberger M (August 2010). “Medullary thyroid carcinoma”. Clin Oncol (R Coll Radiol). 22 (6): 475–85. doi:10.1016/j.clon.2010.05.002. PMID 20627492.
- ↑ Roy M, Chen H, Sippel RS (2013). “Current understanding and management of medullary thyroid cancer”. Oncologist. 18 (10): 1093–100. doi:10.1634/theoncologist.2013-0053. PMC 3805151. PMID 24037980.
- ↑ Mian C, Perrino M, Colombo C, Cavedon E, Pennelli G, Ferrero S, De Leo S, Sarais C, Cacciatore C, Manfredi GI, Verga U, Iacobone M, De Pasquale L, Pelizzo MR, Vicentini L, Persani L, Fugazzola L (May 2014). “Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety”. J. Clin. Endocrinol. Metab. 99 (5): 1656–64. doi:10.1210/jc.2013-4088. PMID 24552221.
- ↑ Bae YJ, Schaab M, Kratzsch J (2015). “Calcitonin as Biomarker for the Medullary Thyroid Carcinoma”. Recent Results Cancer Res. 204: 117–37. doi:10.1007/978-3-319-22542-5_5. PMID 26494386.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Epidemiology and Demographics
Prevalence
- In 2006, the lifetime prevalence of Anaphylaxis was estimated to be 0.05% to 2% in the United States. However it is believed that this is an underestimation because the disease is underdiagnosed. [1]
Case-fatality rate/Mortality rate
- The mortality rate of Anaphylaxis is approximately 186 to 225 deaths/year. [2]
Age
- Patients of all age groups may develop anaphylaxis, however, children and adolescents account for the majority of cases.[3]
Race
- There is no racial predilection to anaphylaxis.
Gender
- Anaphylaxis affects men and women equally with more women being admitted to the hospital for the disease. [1]
Region
- There is no regional predilection to anaphylaxis.
Developed Countries
An estimated 1.24% to 16.8% of the United States population is considered at risk for developing anaphylaxis if they are exposed to one or more allergens. Anaphylaxis results in fewer than 1,000 deaths per year in the U.S and the most common presentation is cardiovascular collapse [4] [5]
References
- ↑ 1.0 1.1 LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Ma L, Danoff TM, Borish L (2014). “Case fatality and population mortality associated with anaphylaxis in the United States”. J Allergy Clin Immunol. 133 (4): 1075–83. doi:10.1016/j.jaci.2013.10.029. PMC 3972293. PMID 24332862.
- ↑ Lieberman P, Camargo CA, Bohlke K, Jick H, Miller RL, Sheikh A; et al. (2006). “Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group”. Ann Allergy Asthma Immunol. 97 (5): 596–602. doi:10.1016/S1081-1206(10)61086-1. PMID 17165265.
- ↑ Neugut, Alfred, Anita Ghatak and Rachel Miller. “Anaphylaxis in the United States: An Investigation Into Its Epidemiology.” Arch Intern Med. 161.108 January 2001 15-21. 29 January 2007 <http://archinte.ama-assn.org/cgi/content/full/161/1/15>.
- ↑ “FASTSTATS – Deaths and Mortality”. Retrieved 2013-02-13.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Common risk factors in the development of anaphylaxis include those related to age, sex, exposure, and other comorbid conditions such as asthma. Delayed use of epinephrine to treat anaphylaxis places patients at increased risk of being hospitalized whereas timely use decreases this risk. [1] Patients that have features of increased risk towards anaphylaxis should be advised to carry auto-injectable epinephrine. [2]
Risk Factors
Common risk factors in the development of anaphylaxis include age, sex, geography, history of asthma, atopic history, and interruption of medication.[3] [4] [5] [6] [7]
Common Risk Factors
- Common risk factors in the development of anaphylaxis include:
- Age, with more incidence in boys younger than 15 and women older than 15 years old.
- Sex, with more incidence in women exposed to latex and aspirin; men have more incidence with venom stings.
- Geography, the incidence of anaphylaxis is higher in Northern areas.
- History of asthma places patients at higher risk to develop anaphylaxis.
- History of atopy increases the risk of anaphylaxis.
- Interruption of medications after desensitization can increase the risk of anaphylaxis.
Less Common Risk Factors
- Less common risk factors in the development of anaphylaxis include:
- Comorbid ischemic dilated cardiomyopathy or coronary arterial disease
- Antihypertensive medication use
- Tricyclic antidepressant medication use
- Monoamine oxidase inhibitor medication use
- Mastocytosis
- Chronic Obstructive Pulmonary Disease
- Upper Respiratory tract infection
- Emotional stress
- Fever
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). “Digitoxin metabolism by rat liver microsomes”. Biochem Pharmacol. 24 (17): 1639–41. PMID https://doi.org/10.1542/peds.2016-4006 DOI: https://doi.org/10.1542/peds.2016-4006 Check
|pmid=value (help). - ↑ Commins SP (2017). “Outpatient Emergencies: Anaphylaxis”. Med Clin North Am. 101 (3): 521–536. doi:10.1016/j.mcna.2016.12.003. PMC 5381731. PMID 28372711.
- ↑ LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Theoharides TC, Valent P, Akin C (2015). “Mast Cells, Mastocytosis, and Related Disorders”. N Engl J Med. 373 (2): 163–72. doi:10.1056/NEJMra1409760. PMID 26154789.
- ↑ Akin C (2017). “Mast cell activation syndromes”. J Allergy Clin Immunol. 140 (2): 349–355. doi:10.1016/j.jaci.2017.06.007. PMID 28780942.
- ↑ Metcalfe DD, Schwartz LB (2009). “Assessing anaphylactic risk? Consider mast cell clonality”. J Allergy Clin Immunol. 123 (3): 687–8. doi:10.1016/j.jaci.2009.02.003. PMC 2782434. PMID 19281912.
- ↑ Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J; et al. (2011). “World Allergy Organization anaphylaxis guidelines: summary”. J Allergy Clin Immunol. 127 (3): 587-93.e1-22. doi:10.1016/j.jaci.2011.01.038. PMID 21377030.
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Dushka Riaz, MD
Overview
Common complications of anaphylaxis include airway blockage, cardiac arrest, respiratory arrest, and shock. Prognosis is generally good with prompt diagnosis and treatment. It is important to follow up with an allergist to determine the exact cause of the anaphylaxis and advise the patient to avoid it in the future. [1] The main cause of mortality is cardiovascular compromise or airway compromise and is more common in patients with asthma. [2]
Natural History, Complications, and Prognosis
Natural History
- The symptoms of anaphylaxis usually develop within seconds with rapid evolution. It usually carries an unpredictable course and can resolve as quickly as it began. If left untreated, anaphylaxis can progress to respiratory or cardiovascular compromise. [3] [4]
Complications
Possible complications include: [5]
- Airway blockage
- Cardiac arrest (no effective heartbeat)
- Respiratory arrest (no breathing)
- Shock
Prognosis
Anaphylaxis can be fatal without prompt treatment. symptoms generally resolve quickly with prompt treatment. Depending on the availability of epinephrine treatment, the prognosis may vary. [5]
References
- ↑ Campbell RL, Park MA, Kueber MA, Lee S, Hagan JB (2015). “Outcomes of allergy/immunology follow-up after an emergency department evaluation for anaphylaxis”. J Allergy Clin Immunol Pract. 3 (1): 88–93. doi:10.1016/j.jaip.2014.07.011. PMID 25577624.
- ↑ LoVerde D, Iweala OI, Eginli A, Krishnaswamy G (2018). “Anaphylaxis”. Chest. 153 (2): 528–543. doi:10.1016/j.chest.2017.07.033. PMC 6026262. PMID 28800865.
- ↑ Pumphrey RS (2000). “Lessons for management of anaphylaxis from a study of fatal reactions”. Clin Exp Allergy. 30 (8): 1144–50. doi:10.1046/j.1365-2222.2000.00864.x. PMID 10931122.
- ↑ Simons FE (2006). “Anaphylaxis, killer allergy: long-term management in the community”. J Allergy Clin Immunol. 117 (2): 367–77. doi:10.1016/j.jaci.2005.12.002. PMID 16461138.
- ↑ 5.0 5.1 “StatPearls”. 2021. PMID 29489197.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Primary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
